Skip to content

Use Of Carcinosinum Homoeopathy Medicine With Family History Of Cancer In Children.

Role Of Carcinosinum in Treatment Of Paediatric Cases With Family History Of Cancer – A Single Arm Interventional, Prospective Study - Nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/066686
Enrollment
30
Registered
2024-05-03
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Z809- Family history of malignant neoplasm, unspecified

Interventions

Intervention1: Carcinosinum Medicine In Indicated Cases: Carcinosinum Medicine will be prescribe when it is indicated along with the family history of Cancer. Dose and frequency will be selected as pe

Sponsors

National Institute Of Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Children In The Age Group 1-18 Years. 2. Patient Of All Sexes 3. Children With Family History Of Cancer With The Symptom Of Carcinosinum. 4. Patient’s Parents/Guardians Willing To Give Written Informed Consent And The Patients Willing To Give Verbal Assent (Children Aged Between 7-12 Years) And Or Written Assent (Children Aged Between 12-17 Years). 5. Parents/Guardians Of Patients With Ability To Read Bengali Or English or Hindi

Exclusion criteria

Exclusion criteria: 1. Children In The Age Group 1-18 Who Doesn’t Meet The Symptom Of Carcinosinum With Family History Of Cancer. 2. Children In The Age Group 1-18 Meeting The Criteria Of Carcinosinum But Doesn’t Have Family History Of Cancer 3. Children on substance abuse. 4. Critically ill patient, immuno-compromised patient. 5. Diagnosed cases of unstable mental or psychiatric illness. 6. Patients / Parents / Guardians of patient unwilling to give consent 7. Patients who are under medications in the past 4 weeks-washout perio

Design outcomes

Primary

MeasureTime frame
Measure Yourself Medical Outcome Profile (MYMOP-2) (Initial) and MYMOP-2 (Follow-up).Timepoint: Baseline and 6 months

Secondary

MeasureTime frame
Outcome in Relation to Impact on Daily Living (ORIDL) is a patient-rated outcome measure;Timepoint: 6 months

Countries

India

Contacts

Public ContactDr K Vijaynanth

National Institute Of Homoeopathy

vjananth74@gmail.com8584888058

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026